0000914475-24-000011.txt : 20240124 0000914475-24-000011.hdr.sgml : 20240124 20240124174714 ACCESSION NUMBER: 0000914475-24-000011 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lippoldt Darin CENTRAL INDEX KEY: 0001504783 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24558006 MAIL ADDRESS: STREET 1: C/O VOLCANO CORPORATION STREET 2: 3661 VALLEY CENTRE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1706136421.xml FORM 4 X0508 4 2024-01-22 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001504783 Lippoldt Darin 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Legal Officer 1 Common Stock 2024-01-22 4 M 0 10000 79.02 A 45882 D Common Stock 2024-01-22 4 S 0 10000 139.8553 D 35882 D Non-Qualified Stock Option 79.02 2024-01-22 4 M 0 10000 79.02 D 2032-01-31 Common Stock 10000 53372 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.80 to $139.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. /s/ Darin Lippoldt 2024-01-24